28 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am
to manufacturing and regulatory activities in support of the Company’s CAN-2409 programs, offset by lower pre-clinical costs and personnel-related expenses
8-K
EX-99.1
CADL
Candel Therapeutics Inc
5 Aug 22
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am
with Silicon Valley Bank in February 2022, offset by costs to fund operating activities and the purchase of fixed assets. Based on current plans
8-K
EX-99.1
CADL
Candel Therapeutics Inc
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
of 2022. The decrease was primarily due to lower recruiting and insurance costs, partially offset by an increase in professional service
8-K
EX-99.1
CADL
Candel Therapeutics Inc
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
insurance and recruiting costs, which were partially offset by increased employee-related expenses. General and administrative expenses included non
8-K
EX-99.1
CADL
Candel Therapeutics Inc
14 May 24
Candel Therapeutics Reports First Quarter 2024 Financial Results
8:15am
following the corporate restructuring in the fourth quarter of 2023 and lower insurance costs. These decreases were partially offset by increased
CORRESP
54kegn3an6t7tt1 wwl5
7 Jul 21
Correspondence with SEC
12:00am
S-1/A
EX-10.10
nsgw8j9p
16 Jul 21
IPO registration (amended)
6:07am
S-1
EX-10.10
2be4i6xnvbm4
25 Jun 21
IPO registration
5:28pm
S-1/A
rfj09f369an47 cg3
16 Jul 21
IPO registration (amended)
6:07am
S-1
t48tkqux
25 Jun 21
IPO registration
5:28pm